secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001558370-25-011143
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio Q2 net loss narrows to $9.4M; cash runway into Q1 2027
------------------------------------------------------------------

- Cash, cash equivalents and marketable securities: $57.6M as of June 30, 2025 vs $91.8M a year ago; runway into Q1 2027.
- Net loss of $9.4M ($2.96 per share) vs $16.0M ($5.09 per share) in Q2 2024 (adjusted for 1-for-20 reverse split).
- Completed dosing of FTD-GRN Cohort 2 in upliFT-D study; all four patients treated with PBFT02.
- Updated interim data: PBFT02 showed robust, durable CSF PGRN elevation and improved plasma NfL biomarker vs natural history.
- Amended upliFT-D protocol submitted to trial sites and health authorities; plan to enroll Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/0001558370-25-011143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/pasg-20250812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer